Added to YB: 2026-07-02
Pitch date: 2026-06-30
MDP.TO [neutral]
Medexus Pharmaceuticals Inc.
+5.83%
current return
Author Info
No bio for this author
Company Info
Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on various therapeutic areas comprising allergy, dermatology, hematology, oncology, rheumatology, and rare diseases.
Market Cap
CAD 113.3M
Pitch Price
CAD 5.15
Price Target
N/A
Dividend
N/A
EV/EBITDA
8.29
P/E
-48.30
EV/Sales
1.30
Sector
Pharmaceuticals
Category
growth
Weekly #11: Most Interesting D-Sheets from the Past Week - Medexus Pharmaceuticals Inc.
MDP.TO (update): North American rare-disease pharma pivoting to GRAFAPEX (allo-HSCT drug). FY26 rev -8.3% to $99.3M, adj EBITDA $16.5M, GAAP loss on Gleolan return/Rupall generics, but Q4 adj EBITDA +87%, GM 53.8%. GRAFAPEX guided ~2.7x to $30-32M FY27; 54/74 centers reordered. Net debt/EBITDA 0.95x, buying back stock. Risks: cash fell to $6.5M, rising R&D/SG&A, lumpy quarters. ~$94.6M cap.
Read full article (1 min)